V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10463139 | 10072431 | 1.55 | 75.5 | Palliative (P) | 2018-02-07 | 2018-03-01 | null | 02 | N | BEXAROTENE | 100821151 |
| 10463388 | 10072432 | 1.67 | 80 | Adjuvant (A) | 2020-08-15 | 2021-11-14 | SOTORASIB | 02 | N | BORTEZOMIB + MELPHALAN | 100668308 |
| 10463797 | 10072433 | 1.84 | 0 | 03 | 2017-07-01 | 2017-07-15 | Arsenic Triox + Tretinoin Ind W5-8 | N | N | TRAMETINIB | 100361329 |
| 10464960 | 10072434 | 1.92 | 49.4 | 03 | 2022-01-29 | 2022-03-10 | CHLVPP | null | N | RIALTO TRIAL | 101572022 |
| 10465735 | 10072435 | 1.51 | 89.5 | Curative (C) | 2021-05-09 | 2021-05-09 | Chlorambucil + Pred + Rituximab | 02 | N | CAPECITABINE + CARBOPLATIN + EPIRUBICIN | 101320526 |
| 10465757 | 10072436 | null | null | Palliative (P) | 2021-07-25 | 2021-08-07 | Bevacizumab | 2 | N | DOXORUBICIN + IFOSFAMIDE | 101283390 |
| 10466432 | 10072437 | 1.53 | 81.2 | null | 2017-08-26 | 2017-08-27 | MITOMYCIN | 02 | null | OSIMERTINIB | 101256506 |
| 10467214 | 10072439 | null | null | null | 2022-03-11 | 2022-03-24 | STAMPEDE TRIAL | 02 | null | BOSUTINIB | 101200479 |
| 10468857 | 10072440 | null | null | null | null | 2020-02-18 | Vinblastine | 01 | null | LENALIDOMIDE + RITUXIMAB | 101815249 |
| 10472643 | 10072443 | 1.64 | 99 | null | 2021-03-27 | 2021-04-15 | DOCETAXEL + FLUOROURACIL + OXALIPLATIN | 01 | null | BOSUTINIB | 100471881 |
| 10476699 | 10072448 | 1.84 | 75 | null | 2021-05-07 | 2021-05-08 | MITOMYCIN | 02 | null | PACLITAXEL + TRASTUZUMAB | 101630583 |
| 10477608 | 10072450 | 1.5 | 95.2 | 03 | 2020-04-23 | 2020-04-24 | null | 02 | N | CARBOPLATIN + FLUOROURACIL | 100258500 |
| 10478176 | 10072452 | 1.78 | 102.5 | null | 2021-09-29 | 2022-05-12 | ISATUXIMAB + POMALIDOMIDE | 02 | null | EVEROLIMUS | 100836889 |
| 10115321 | 10072455 | null | null | null | 2022-02-20 | 2022-02-28 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 99 | N | CYCLOPHOSPHAMIDE HIGH DOSE | 101842694 |
| 10133733 | 10072456 | 1.77 | 62.6 | null | null | 2020-02-03 | Capecitabine + Mitomycin | 02 | null | NINTEDANIB | 101578948 |
| 10172452 | 10072460 | 1.63 | 71.1 | Palliative (P) | 2019-03-31 | 2019-04-01 | FLAIR Trial | 02 | N | THALIDOMIDE | 100916754 |
| 10179413 | 10072462 | 1.93 | 60.2 | 03 | null | 2020-06-03 | Durvalumab | 02 | N | OSIMERTINIB | 101002447 |
| 10186892 | 10072463 | 1.64 | 77.8 | null | 2018-09-27 | 2018-09-28 | BELANTAMAB MAFODOTIN | 02 | null | LENALIDOMIDE + RITUXIMAB | 100272932 |
| 10194595 | 10072465 | 1.59 | 57.5 | null | 2020-01-05 | 2020-01-11 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 02 | null | PEMBROLIZUMAB + PEMETREXED | 100647434 |
| 10240488 | 10072467 | 1.64 | 67.8 | 03 | 2018-08-31 | 2019-11-21 | Erlotinib | 02 | null | IDELALISIB | 101791713 |
| 10245092 | 10072468 | 1.8 | 59 | 03 | 2018-09-16 | 2018-09-16 | PARTNER Trial | 02 | N | CARFILZOMIB | 100537325 |
| 10257267 | 10072469 | 1.57 | 92 | null | 2020-08-27 | 2021-02-27 | CARFILZOMIB | N | null | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE + RITUXIMAB | 101351999 |
| 10257579 | 10072470 | 1.62 | 72.3 | 03 | 2022-03-05 | 2022-03-19 | Ipilimumab | 02 | N | CAPECITABINE + CARBOPLATIN | 101654023 |
| 10275478 | 10072472 | 1.58 | 85.6 | null | 2018-12-05 | 2019-04-24 | null | 02 | null | ETOPOSIDE | 101464786 |
| 10277622 | 10072474 | 1.63 | 91 | null | 2020-08-05 | 2022-04-24 | Methotrexate High Dose (3g/m2) | 02 | null | OCTREOTIDE | 100962482 |
| 10285735 | 10072476 | 1.5 | 54 | Palliative (P) | 2020-02-13 | 2020-02-13 | Ipilimumab | 02 | N | IDELALISIB + RITUXIMAB | 100919886 |
| 10293663 | 10072477 | 1.66 | 56.7 | null | null | 2021-05-10 | Cetuximab + Encorafenib | 02 | null | MUK8 TRIAL | 101641490 |
| 10297559 | 10072478 | 1.78 | 67.55 | null | 2019-12-10 | 2020-11-25 | CAPECITABINE + CARBOPLATIN + Trastuzumab | 02 | null | CISPLATIN + DOCETAXEL + FLUOROURACIL | 100394923 |
| 10302602 | 10072480 | 1.64 | 66 | null | 2012-10-27 | 2020-03-16 | Cyclophosphamide + Docetaxel + Trastuzumab | 02 | null | BOSUTINIB | 100733846 |
| 10335464 | 10072483 | 1.62 | 64.45 | null | 2020-06-28 | 2020-09-07 | CAR-T Yescarta + Fludarabine + Cyclophosphamide | 02 | null | CARBOPLATIN + PACLITAXEL + PEMBROLIZUMAB | 100837378 |
| 10336205 | 10072484 | 0 | 0 | null | 2020-08-29 | 2020-08-29 | CHOP R + METHOTREXATE | 02 | null | DURVALUMAB | 101294257 |
| 10337274 | 10072485 | 1.8 | 59 | Curative (C) | 2020-01-04 | 2020-01-06 | Brentuximab | 02 | N | THALIDOMIDE | 100832100 |
| 10359844 | 10072492 | 1.7 | 57 | 03 | 2021-09-24 | 2022-02-22 | CAR-T Tecartus + Cyclophosphamide + Fludarabine | 02 | N | PONATINIB | 101704836 |
| 10360895 | 10072493 | 1.75 | 77.7 | Palliative (P) | 2018-10-05 | 2018-10-05 | DA-EPOCH-R | 02 | N | CAPECITABINE + CARBOPLATIN | 101609114 |
| 10362044 | 10072494 | 1.69 | 0 | 03 | 2020-12-01 | 2020-12-01 | IDELALISIB | 02 | N | BEVACIZUMAB | 101165589 |
| 10381938 | 10072495 | null | 65.1 | Curative (C) | 2020-11-19 | 2021-10-07 | TRANSPLANT ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 02 | N | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN | 101748891 |
| 10391097 | 10072497 | 1.59 | 0 | 03 | 2020-08-26 | 2020-08-26 | Cyclophosphamide + Fudarabine + Tisagenlecleucel | 02 | N | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB | 101266589 |
| 10407907 | 10072500 | 1.72 | 77.7 | Palliative (P) | 2017-12-04 | 2020-06-26 | CARBOPLATIN + FLUOROURACIL | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100734335 |
| 10417622 | 10072503 | 1.55 | 70.9 | null | null | 2021-04-06 | SAPROCAN TRIAL | null | null | OXALIPLATIN + MDG | 101605680 |
| 10421790 | 10072504 | null | 79 | null | null | 2019-09-01 | CHOP R | 02 | null | DOXORUBICIN EMBOLISATION | 100885565 |
| 10431345 | 10072506 | null | 71 | null | 2018-01-25 | 2018-02-14 | null | 02 | null | CHLORAMBUCIL + ETOPOSIDE | 101540212 |
| 10453660 | 10072509 | 0 | 59.3 | null | 2017-02-11 | 2017-02-16 | CVP R | 02 | null | BRENTUXIMAB | 101746091 |
| 10475499 | 10072514 | 1.71 | 77.3 | null | 2019-11-20 | 2019-11-22 | Irinotecan + Modified De Gramont | 02 | null | EVEROLIMUS + EXEMESTANE | 101779506 |
| 10219469 | 10072517 | 1.67 | 77.3 | null | 2021-05-03 | 2021-05-03 | Pemetrexed | 02 | N | AML19 TRIAL | 101437340 |
| 10231904 | 10072518 | 1.7 | 60.6 | null | 2020-02-24 | 2020-02-28 | CISPLATIN + FLUOROURACIL + RT | 02 | null | FLUOROURACIL + MITOMYCIN | 101636948 |
| 10330421 | 10072523 | 0 | 86 | Disease modification (D) | 2021-10-27 | 2021-10-27 | EVEROLIMUS + EXEMESTANE | 01 | N | IPILIMUMAB | 100171223 |
| 10410151 | 10072526 | 1.72 | 75.2 | 03 | 2020-01-16 | 2020-01-24 | Neratinib | 02 | N | CYCLOPHOSPHAMIDE + VINCRISTINE | 100800127 |
| 10418246 | 10072698 | 1.8 | null | null | 2019-12-31 | 2019-12-31 | Rituximab | null | null | RITUXIMAB | 100298252 |
| 10418285 | 10072699 | 1.52 | 72.3 | null | 2020-10-01 | 2021-06-21 | IBRUTINIB | 02 | null | IBRUTINIB | 101033243 |
| 10418529 | 10072700 | 1.52 | 74.5 | null | 2019-10-19 | 2021-04-24 | IBRUTINIB | 02 | null | IBRUTINIB | 100383815 |